These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 15954440)

  • 61. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
    Fiocco U; Sfriso P; Oliviero F; Pagnin E; Scagliori E; Campana C; Dainese S; Cozzi L; Punzi L
    Autoimmun Rev; 2008 Oct; 8(1):76-82. PubMed ID: 18718877
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The inhibitor of costimulation of T cells: abatacept.
    Iannone F; Lapadula G
    J Rheumatol Suppl; 2012 Jul; 89():100-2. PubMed ID: 22751606
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Costimulation blockade in autoimmunity and transplantation.
    Vincenti F
    J Allergy Clin Immunol; 2008 Feb; 121(2):299-306; quiz 307-8. PubMed ID: 18269922
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease.
    Green JM
    Am J Respir Cell Mol Biol; 2000 Mar; 22(3):261-4. PubMed ID: 10696061
    [No Abstract]   [Full Text] [Related]  

  • 65. The B7-CD28 superfamily.
    Sharpe AH; Freeman GJ
    Nat Rev Immunol; 2002 Feb; 2(2):116-26. PubMed ID: 11910893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
    Yasuoka Y; Goto A; Seriu T
    Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):87-94. PubMed ID: 21321458
    [No Abstract]   [Full Text] [Related]  

  • 68. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis.
    Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):381-91, viii. PubMed ID: 15172047
    [TBL] [Abstract][Full Text] [Related]  

  • 69. T-cell-activation inhibitors in rheumatoid arthritis.
    Lorenz HM
    BioDrugs; 2003; 17(4):263-70. PubMed ID: 12899643
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [CTLA4-Ig].
    Miyasaka N
    Nihon Rinsho; 2005 May; 63 Suppl 5():751-5. PubMed ID: 15954440
    [No Abstract]   [Full Text] [Related]  

  • 71. Abatacept mechanism of action: concordance with its clinical profile.
    Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
    Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
    [TBL] [Abstract][Full Text] [Related]  

  • 74. T-cell regulation by CD28 and CTLA-4.
    Alegre ML; Frauwirth KA; Thompson CB
    Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.